Trial Profile
A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMPACT
- 02 Nov 2021 Results assessing efficacy of gefitinib as an adjuvant therapy for non-small-cell lung cancer patients with EGFR mutation published in the Journal of Clinical Oncology
- 08 Jun 2021 Primary endpoint has not been met (Disease free survival) , according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology